New combo therapy aims to stop liver cancer from coming back
NCT ID NCT07487662
Summary
This study tests different combinations of treatments given before surgery for liver cancer that can be removed. The goal is to see if adding immunotherapy drugs and/or a targeted drug to standard local treatments (like TACE or ablation) can help keep the cancer from returning after surgery. It will involve 90 adults with early-to-mid stage liver cancer who have not had prior treatment and are at a higher risk of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.